{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:12:44Z","timestamp":1792714364648,"version":"4.5.0"},"reference-count":82,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T00:00:00Z","timestamp":1288742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0013821","type":"journal-article","created":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T16:22:37Z","timestamp":1288801357000},"page":"e13821","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":272,"title":["FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy"],"prefix":"10.1371","volume":"5","author":[{"given":"Lucie C.","family":"Kompier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lurkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelon N. M.","family":"van der Aa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W. G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo H.","family":"van der Kwast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen C.","family":"Zwarthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,11,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002.","volume":"55","author":"DM Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.urolonc.2007.05.011","article-title":"Targeted therapies in bladder cancer\u2013an update.","volume":"25","author":"PC Black","year":"2007","journal-title":"Urol Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1038\/sj.onc.1210399","article-title":"Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.","volume":"26","author":"DC Tomlinson","year":"2007","journal-title":"Oncogene"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.459.11.2","article-title":"Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.","volume":"11","author":"JJ Gomez-Roman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/1535-7163.MCT-07-0394","article-title":"Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.","volume":"7","author":"JL Martinez-Torrecuadrada","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/jpet.109.162768","article-title":"1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3 -d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27\/Kip1 and G1\/G0 arrest.","volume":"332","author":"M Miyake","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.juro.2007.08.087","article-title":"Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer.","volume":"179","author":"W Kassouf","year":"2008","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000282357","article-title":"Epidermal growth factor receptor and bladder cancer: a review.","volume":"48","author":"DE Neal","year":"1992","journal-title":"Urol Int"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00345-007-0202-7","article-title":"Targeting EGFR in bladder cancer.","volume":"25","author":"GJ Villares","year":"2007","journal-title":"World J Urol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/jnci\/djp280","article-title":"Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.","volume":"101","author":"S Siena","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/0008-5472.CAN-08-2466","article-title":"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.","volume":"69","author":"A Sartore-Bianchi","year":"2009","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2141.2004.04814.x","article-title":"Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.","volume":"124","author":"JL Paterson","year":"2004","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2006-04-017087","article-title":"MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.","volume":"108","author":"E Masih-Khan","year":"2006","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"10524","DOI":"10.1158\/0008-5472.CAN-05-1536","article-title":"Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.","volume":"65","author":"W Kassouf","year":"2005","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/bjc.1993.147","article-title":"The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group.","volume":"67","author":"LA Kiemeney","year":"1993","journal-title":"Br J Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1464-410x.2000.00547.x","article-title":"Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression.","volume":"85","author":"K Zieger","year":"2000","journal-title":"BJU Int"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/path.2507","article-title":"The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.","volume":"218","author":"LC Kompier","year":"2009","journal-title":"J Pathol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.","volume":"54","author":"M Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"ref19","first-page":"260","article-title":"Evaluation of pain caused by urethrocystoscopy in patients with superficial bladder cancer: a perspective of quality of life.","volume":"28","author":"T Muezzinoglu","year":"2005","journal-title":"Onkologie"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1464-410X.2007.07224.x","article-title":"Patients&apos; perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison.","volume":"101","author":"MN van der Aa","year":"2008","journal-title":"BJU Int"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0090-4295(00)00777-9","article-title":"Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis.","volume":"56","author":"JL Vriesema","year":"2000","journal-title":"Urology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature.","volume":"21","author":"MF Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/00005650-199508000-00007","article-title":"Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis.","volume":"33","author":"GF Riley","year":"1995","journal-title":"Med Care"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5489\/cuaj.600","article-title":"Biomarkers for detection and surveillance of bladder cancer.","volume":"2","author":"LI Budman","year":"2008","journal-title":"Can Urol Assoc J"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.urolonc.2009.11.004","article-title":"Considerations on implementing diagnostic markers into clinical decision making in bladder cancer.","volume":"28","author":"Y Lotan","year":"2010","journal-title":"Urol Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/03008880802283953","article-title":"Detection of tumours of the urinary tract in voided urine.","author":"EC Zwarthoff","year":"2008","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncy.20080","article-title":"A review on the current state of urine cytology emphasizing the role of fluorescence in situ hybridization as an adjunct to diagnosis.","volume":"118","author":"NP Caraway","year":"2010","journal-title":"Cancer Cytopathol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1442-2042.2008.02174.x","article-title":"Bladder cancer biomarkers and their role in surveillance and screening.","volume":"16","author":"AA Van Tilborg","year":"2009","journal-title":"Int J Urol"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399410001407","article-title":"Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).","volume":"12","author":"C Pollard","year":"2010","journal-title":"Expert Rev Mol Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/ijc.21852","article-title":"Understanding urothelial carcinoma through cancer pathways.","volume":"119","author":"WA Schulz","year":"2006","journal-title":"Int J Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.","volume":"158","author":"C Billerey","year":"2001","journal-title":"Am J Pathol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1200\/JCO.2003.05.073","article-title":"Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.","volume":"21","author":"BW van Rhijn","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1074\/jbc.272.10.6621","article-title":"Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein.","volume":"272","author":"M Kanai","year":"1997","journal-title":"J Biol Chem"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1091\/mbc.12.4.931","article-title":"Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.","volume":"12","author":"KC Hart","year":"2001","journal-title":"Mol Biol Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1038\/sj.onc.1206798","article-title":"The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.","volume":"22","author":"YM Agazie","year":"2003","journal-title":"Oncogene"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nm971","article-title":"Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway.","volume":"10","author":"A Yasoda","year":"2004","journal-title":"Nat Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1038\/onc.2009.280","article-title":"Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.","volume":"28","author":"E di Martino","year":"2009","journal-title":"Oncogene"},{"key":"ref38","first-page":"8108","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.","volume":"63","author":"AA Bakkar","year":"2003","journal-title":"Cancer Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.","volume":"64","author":"BW van Rhijn","year":"2004","journal-title":"Cancer Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.","volume":"66","author":"E Lopez-Knowles","year":"2006","journal-title":"Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.","volume":"15","author":"FM Platt","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.","volume":"24","author":"AH Jebar","year":"2005","journal-title":"Oncogene"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1349-7006.2006.00343.x","article-title":"PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.","volume":"97","author":"K Kozaki","year":"2006","journal-title":"Cancer Sci"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1200\/JCO.2008.18.6544","article-title":"PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.","volume":"27","author":"S Ogino","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","article-title":"Oncogenic PI3K and its role in cancer.","volume":"18","author":"Y Samuels","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1210\/jc.2007-1076","article-title":"Phosphatidylinositol 3-kinase\/akt and ras\/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.","volume":"93","author":"L Santarpia","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"13450","DOI":"10.1073\/pnas.0705218104","article-title":"Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.","volume":"104","author":"C Hafner","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2133.2008.08963.x","article-title":"FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo.","volume":"160","author":"C Hafner","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000471722","article-title":"Correlation between the expression of the P21 ras oncogene product and the biological behavior of bladder tumors.","volume":"20","author":"TJ Miao","year":"1991","journal-title":"Eur Urol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000281520","article-title":"Expression of ras p21 oncogene product on human bladder tumors.","volume":"44","author":"N Moriyama","year":"1989","journal-title":"Urol Int"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00295190","article-title":"Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors.","volume":"21","author":"DW Ye","year":"1993","journal-title":"Urol Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.eururo.2009.09.013","article-title":"Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.","volume":"57","author":"M Birkhahn","year":"2010","journal-title":"Eur Urol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1158\/1078-0432.CCR-05-1045","article-title":"A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.","volume":"11","author":"JM van Oers","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref54","article-title":"FGFR3 mutation analysis on voided urine for surveillance of patients with low grade non-muscle invasive bladder cancer.","author":"TCM Zuiverloon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1756-0500-2-66","article-title":"A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene.","volume":"2","author":"CD Hurst","year":"2009","journal-title":"BMC Res Notes"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"e8802","DOI":"10.1371\/journal.pone.0008802","article-title":"Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.","volume":"5","author":"I Lurkin","year":"2010","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9","article-title":"TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer.","volume":"80","author":"LH Sobin","year":"1997","journal-title":"Cancer"},{"key":"ref58","article-title":"Histological Typing of Urinary Bladder Tumours.","author":"FK Mostofi","year":"1973"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2006.04.011","article-title":"Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.","volume":"31","author":"CI Muller","year":"2007","journal-title":"Leuk Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1464-410X.2007.06927.x","article-title":"Prognostic significance of p27Kip1 expression in bladder cancer.","volume":"100","author":"F Rabbani","year":"2007","journal-title":"BJU Int"},{"key":"ref61","article-title":"CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma.","author":"YK Ye","year":"2010","journal-title":"Clin Exp Med"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/1097-0215(20000815)87:4<522::AID-IJC10>3.0.CO;2-X","article-title":"Allelic losses demonstrate monoclonality of multifocal bladder tumors.","volume":"87","author":"J Louhelainen","year":"2000","journal-title":"Int J Cancer"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM199203123261104","article-title":"Clonal origin bladder cancer.","volume":"326","author":"D Sidransky","year":"1992","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/hmg\/9.20.2973","article-title":"Molecular evolution of multiple recurrent cancers of the bladder.","volume":"9","author":"AA van Tilborg","year":"2000","journal-title":"Hum Mol Genet"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2008.06.013","article-title":"FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.","volume":"55","author":"JM van Oers","year":"2009","journal-title":"Eur Urol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.juro.2007.03.034","article-title":"A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.","volume":"178","author":"HB Grossman","year":"2007","journal-title":"J Urol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/01.ju.0000169257.19841.2a","article-title":"Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.","volume":"174","author":"D Jocham","year":"2005","journal-title":"J Urol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.pathol.4.110807.092230","article-title":"Molecular pathogenesis and diagnostics of bladder cancer.","volume":"4","author":"AP Mitra","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10555-009-9198-3","article-title":"Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.","volume":"28","author":"MA Knowles","year":"2009","journal-title":"Cancer Metastasis Rev"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","article-title":"Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.","volume":"6","author":"M Cully","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth.","volume":"441","author":"RJ Shaw","year":"2006","journal-title":"Nature"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/370527a0","article-title":"Phosphatidylinositol-3-OH kinase as a direct target of Ras.","volume":"370","author":"P Rodriguez-Viciana","year":"1994","journal-title":"Nature"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0092-8674(00)00196-3","article-title":"Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma.","volume":"103","author":"ME Pacold","year":"2000","journal-title":"Cell"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"37398","DOI":"10.1074\/jbc.M405730200","article-title":"Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK.","volume":"279","author":"W Li","year":"2004","journal-title":"J Biol Chem"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"24052","DOI":"10.1074\/jbc.273.37.24052","article-title":"Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase.","volume":"273","author":"J Yan","year":"1998","journal-title":"J Biol Chem"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.4161\/cc.6.23.4996","article-title":"Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis.","volume":"6","author":"AR Ramjaun","year":"2007","journal-title":"Cell Cycle"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbrc.2009.02.081","article-title":"Functional differences between two classes of oncogenic mutation in the PIK3CA gene.","volume":"381","author":"C Chaussade","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1073\/pnas.0701005104","article-title":"Rare cancer-specific mutations in PIK3CA show gain of function.","volume":"104","author":"M Gymnopoulos","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1073\/pnas.0712169105","article-title":"Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.","volume":"105","author":"L Zhao","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.","volume":"213","author":"DC Tomlinson","year":"2007","journal-title":"J Pathol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.","volume":"14","author":"JA Engelman","year":"2008","journal-title":"Nat Med"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.","volume":"69","author":"S Wee","year":"2009","journal-title":"Cancer Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0013821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T23:27:30Z","timestamp":1685834850000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0013821"}},"subtitle":[],"editor":[{"given":"Venugopalan","family":"Cheriyath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,11,3]]},"references-count":82,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2010,11,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0013821","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,3]]}}}